Bio Pro Classes:

Monday, 12 Oct 2015
Category: Bio Pro Classes

Tuesday, 13 Oct 2015
Category: Bio Pro Classes

Thursday, 15 Oct 2015
Category: Bio Pro Classes

Monday, 19 Oct 2015
Category: Bio Pro Classes

Tuesday, 20 Oct 2015 - Wednesday, 21 Oct 2015
Category: Bio Pro Classes

Thursday, 22 Oct 2015
Category: Bio Pro Classes

Thursday, 29 Oct 2015
Category: Bio Pro Classes

Tuesday, 03 Nov 2015
Category: Bio Pro Classes

Wednesday, 04 Nov 2015 - Friday, 06 Nov 2015
Category: Bio Pro Classes

Monday, 09 Nov 2015 - Tuesday, 10 Nov 2015
Category: Bio Pro Classes

Event Registration Cart

Your cart is empty.

Leukemia & Lymphoma Society Drawing Winners!

Archery Summit:  367832
Exclusive Dining Experience: 367934
Willamette Valley: 367941
ArborBrook: 367960

Please contact Cindy at 503-548-4432 or to arrange pick up.

OR Bio 2014-’15 Annual Report: The Thriving Bio Ecosystem

In 2014, Oregon held steady with a 6% net increase in federal grants from several funding sources such as the National Institutes of Health (NIH), Small Business Technology Transfer Program (STTR), Small Business Innovation Research (SBIR), Department of Defense, and the National Science Foundation.

photo- front page AR 2014-15

View PDF

Wired Magazine Editor, Cambia Grove Founder and Fred Hutch’s President to Appear at Oregon Bio’s ‘Expanding the Ecosystem’ Annual Conference

Internationally known leaders from key companies, funders and organizations, including Epic Semiconductors, Carabiner,  University of California, Davis, Fred Hutchinson Cancer Research Center, Endeavor Partners, and WIRED magazine will present to an anticipated 300 participants in two weeks to share innovation best practices, emerging thought leadership in cannabis medical research, growing the presence of women in STEM, digital health’s local expansion, pharmaceuticals’ valuation, and the opportunities of the bio-cluster at Portland’s central southeast side.


View PDF



News Flash

  • Sedia expands its HIV-1 LAg-Avidity Assay for recent HIV-1 infections to dried blood spot specimens

    The Sedia™ HIV-1 Limiting Antigen Avidity Enzyme Immunoassay, a leading HIV incidence assay, can now be used on dried blood specimens without need for cold chain storage.

    Sedia Biosciences Corporation announced today the commercial launch of a new product, the Sedia™ HIV-1 Limiting Antigen (LAg)-Avidity EIA for Dried Blood Spot Specimens. The new assay supplements its highly regarded HIV incidence assay, the Sedia™ HIV-1 Limiting Antigen (LAg)-Avidity EIA originally designed for liquid serum and plasma specimens. The new assay enables users to test dried blood spot specimens, which are commonly used to collect and ship blood specimens to testing labs in developing countries and other areas without access to cold chain storage. The Sedia™ HIV-1 Limiting Antigen (LAg)-Avidity EIA is the leading commercial HIV incidence assay used by epidemiologists, researchers and public health scientists as an accurate laboratory tool to identify recent infections previously identified as positive. This enables scientists to determine HIV-1 incidence rates in populations to monitor the the spread of the pandemic, identify "hot spots" of infections, assess effectiveness of public health intervention programs and identify suitable populations to evaluate vaccine effectiveness. Sedia sells the assay in over 30 countries.

    The assay application was developed in cooperation with the Centers for Disease Control and Prevention (CDC) who evaluates and approves HIV incidence assays for programs funded by the U.S. Government, such as PEPFAR (the President's Emergency Action Plan for AIDS Relief), a multi-year program to support HIV/AIDS programs in developing countries funded for $6.6 Billion in 2015 alone. Sedia has received approval for two commercial lots of the dried blood spot (DBS) version of the assay to date. The first lot was provided to CDC and for Sedia internal studies, while the second lot, which is now available, is for commercial sale to scientists in other programs.

    Steve Piacentini, Sedia's Director of Assay Development, and Senior Project Manager for the development of both HIV-1 LAg-Avidity EIAs, said, "We were very focused on developing a quality product that can be manufactured on a consistent basis, to ensure the continued supply of the assay for the ongoing needs of the CDC's and other public health groups' programs. Now with the extensive evaluations completed by CDC and the approval they have issued, we look forward to supplying this product to our other customers."

    Dr. Ronald W. Mink, Sedia's President and Chief Science Officer stated, "We are delighted to be able to offer the Sedia™ HIV-1 Limiting Antigen (LAg)-Avidity EIA for DBS to programs reliant on collection of dried blood spots, enabling them to use this cutting edge technology to monitor and manage their programs. Providing this kind of information on these programs is critical to their long-term success in the battle against AIDS globally."

    The Sedia™ HIV-1 Limiting Antigen (LAg)-Avidity EIA including its DBS version, works by quantitatively measuring the maturation of the antibody response, measurind as antibody avidity or "binding strength", as the HIV-1 infection progresses. Recently infected persons produce primarily low-avidity or low binding strength antibodies to the HIV-1 virus, and persons with longer term infections produce more high-avidity antibodies, allowing differentiation between new and established infections. Conventional diagnostic screening tests only indicate that the person is infected, not whether the disease is a new one or one that may have happened years earlier. Sedia Biosciences is the world's leading manufacturer of commercial assays to measure HIV-1 incidence and identify recent infections.

    Research reported in this press release was supported by a Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R44AI097001. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.


    September 21, 2015 
    Sedia Biosciences Corporation

Bioscience News

  • “Know GMO” is a documentary in development meant to provide “an uplifting discussion about food” to help silence the noise and open the ears to facts that Scientists across the world are speaking. Robert Saik is the executive director of the movie project and his son Nick Saik is filming it. The Genetic Literacy Project reported on Saik’s trip to Africa to shoot part of the documentary. According to the GLP, Saik interacted with and interviewed Read More >

  • Hundreds of food and agri-business representatives are in Washington this week visiting with members of the Senate to talk about biotechnology, GMOs, and food labels.  Bob Stallman, president of the American Farm Bureau Federation, explains in The Hill why the Senate needs to act soon to pass a federal GMO food labeling bill: There is a growing anxiety among American farmers, manufacturers and shoppers about confusing and expensive changes coming soon to store shelves unless Read More >

  • Today’s Wall Street Journal story, “Price Increases Drive Drug Firms’ Revenue” reaffirms that old chestnut, “…a little information is a dangerous thing…”  When speaking to the complexities of the costs and benefits of America’s healthcare system, a publication like the Wall Street Journal should not cherry pick one aspect of that system to cover while ignoring the rest. Unfortunately and uncharacteristically, in this case, the paper focused on particular costs while ignoring value. In fact, Read More >

Underwriting Sponsors

Sustaining Sponsors

Principal Sponsors

Home | Bio in Oregon | BioPro Training | Events | Sponsors | Member Resources | News | About Us

Oregon Bioscience Association Copyright © 2015. All Rights Reserved.